Forgot Password?
Return to Course Listing

CME: Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

ACCREDITATION EXPIRED: September 21, 2025

Activity Description / Statement of Need:

In this online, self-learning activity:

Over 64,000 people develop and close 50,000 die each year of pancreatic cancer, and by 2030, pancreatic cancer is expected to surpass colorectal and breast cancer to become the second-leading cause of cancer death. Over 90% of whom have pancreatic ductal adenocarcinoma (PDAC), and while the 5-year survival rate for patients diagnosed with localized disease is over 44%, patients with locally advanced (LAPC) or metastatic disease have a median overall survival of 12 to 14 months. Symptoms associated with pancreatic cancer are not usually evident in the early stages of the disease and may be intermittent and nonspecific, and more than half of patients have advanced disease by the time they are diagnosed.

Target Audience:

HCPs including: medical oncologists; physician assistants, nurse practitioners, nurses, or pharmacists specializing in oncology.


Commercial Support Disclosure: This program is supported by an educational grant from Ipsen Biopharmaceuticals. 

This activity is free of charge.


Release Date: September 21, 2024 -- Expiration Date: September 21, 2025

Faculty: Elizabeta Popa, MD

Agenda

Faculty member introduction, disclosures,

  • Highlights in pre-clinical and molecular testing
  • Highlights in clinical results

Concluding remarks, takeaways

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at the ASCO 2024 annual meeting relating to pancreatic cancer​.
  • Describe advances in disease diagnosis​ and understand progression and prognosis of disease.
  • Evaluate the degree of therapeutic success of trials presented.
  • Quantify benefits of therapy and risk of disease progression in the context of new data.
  • Discuss therapeutic and emerging therapies and be able to apply information to patient cases​.

Accreditation

ACCME Activity #202823471

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Elizabeta C. Popa MD, Assistant Professor of Clinical Medicine, Weill Cornell Medical College, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Ipsen Biopharmaceuticals. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Taking the next step in the management of relapsed or refractory follicular lymphoma

Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC)

Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape